click on circles to display study description...
Tislelizumab (n=-9) vs. docetaxel (n=-9)
randomized controlled trial
Tislelizumab
100 mg per vial, 200mg intravenous (IV), Q3W
Docetaxel
75 mg/m2 IV Q3W
mNSCLC - L2 - all population
open label
P3
powered by vis.js Network